Pulse wave propagation rate and dynamics of matrix metalloproteinase in patients with myocardial infarction and arterial hypertension in the presence or absence of diabetes mellitus

Objective: to study the pulse wave propagation rate and the level of matrix metalloproteinase type 9 in patients with ST-segment elevation myocardial infarction who underwent percutaneous coronary intervention in the presence of hypertension and diabetes mellitus. Materials and methods: the study included 136 patients of both sexes. The first group consisted of 69 patients with STEMI+AH, the second group included 67 patients with acute STEMI+AH+DM2. The patients underwent analysis of the level of matrix metalloproteinase type 9, analysis of pulse wave propagation velocity, Statistical processing of the study results was carried out using Excel spreadsheets and the Statistica 10 statistical software package (StatSoftInc.). Results: at the stationary stage, the level of MMP-9 in the first group ranged from 28 ng/ml to 1340 ng/ml with a median of 297 ng/ml. The level of this indicator above 600 ng/ml is interpreted by statistical analysis as emissions in this distribution. In the second group of patients with DM2, a similar pattern was observed in the distribution of the indicator, but the median value of the indicator was at the level of 387 ng/ml and the observed spread of the indicator was 28–1560 ng/ml statistically significantly higher compared with the first group (p<0.001). The values of MMP-9 are characterized in both the first and second groups by a direct correlation with the level of HbA1c. The analysis of pulse wave propagation velocity revealed a statistically significant difference in pulse wave propagation velocity in muscle-type vessels and the CM ratio/SE between patients of the compared groups. Pulse wave propagation velocity for vessels of the classical type was also statistically significantly higher in the group of patients with diabetes mellitus. Conclusions: the determination of MMP9 and pulse wave propagation velocity levels may become an important method for determining the prognosis in patients with DM2 who have undergone STEMI. The analysis of pulse wave propagation velocity revealed a statistically significant difference in pulse wave propagation velocity in muscle-type vessels and the CM ratio/SE between patients of the compared groups. pulse wave propagation velocity for vessels of the classical type was also statistically significantly higher in the group of patients with diabetes mellitus.

1. Balanova Yu.A., Shalnova S.A., Imaeva A.E., Kapustina А.V., Muromtseva G.A., Evstifeeva S.V., Tarasov V.I., Redko A.N., Viktorova I.A., Prishchepa N.N., Yakushin S.S., Boytsov S.A., Drapkina O.M. Prevalence, Awareness, Treatment and Control of Hypertension in Russian Federation (Data of Observational ESSERF-2 Study). Rational Pharmacotherapy in Cardiology. 2019;15(4):450-466. (In Russ.) https://doi.org/10.20996/1819-6446-2019-15-4-450-466

2. Brodskaya T.A., Nevzorova V.A., Shakhgeldyan K.I., Geltser B.I., Vrazhnov D.A., Kistenev Yu.V. Predictive potential of cardiovascular risk factors and their associations with arterial stiffness in people of European and Korean ethnic groups. Russian Journal of Cardiology. 2021;26(5):4230. (In Russ.) https://doi.org/10.15829/1560-4071-2021-4230

3. Gumerova V.E., Sayganov S.A., Gomonova V.V. Parameters of arterial stiffness in hypertensive patients with and without subclinical carotid atherosclerosis. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2021;27(4):427- 435. (In Russ.) https://doi.org/10.18705/1607-419X-2021-27-4-427-435

4. Asmar R, Topouchian J, Pannier B, Benetos A, Safar M; Scientific, Quality Control, Coordination and Investigation Committees of the Complior Study. Pulse wave velocity as endpoint in large-scale intervention trial. The Complior study. Scientific, Quality Control, Coordination and Investigation Committees of the Complior Study. J Hypertens. 2001;19(4):813-818. https://doi.org/10.1097/00004872-200104000-00019

5. Tolkunova K.M., Rotar O.P., Erina A.M., Boiarinova M.A., Alievа A.S., et al. Supernormal vascular aging — prevalence and determinants at population level (the ESSE-RF data). "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2020;26(2):170-183. (In Russ.) https://doi.org/10.18705/1607-419X-2020-26-2-170-183

6. Jing J, Pan Y, Zhao X, Zheng H, Jia Q, et al. Prognosis of Ischemic Stroke With Newly Diagnosed Diabetes Mellitus According to Hemoglobin A1c Criteria in Chinese Population. Stroke. 2016;47(8):2038-2044. https://doi.org/10.1161/STROKEAHA.116.013606

7. Safar ME, Asmar R, Benetos A, Blacher J, Boutouyrie P, et al. Interaction Between Hypertension and Arterial Stiffness. Hypertension. 2018;72(4):796-805. https://doi.org/10.1161/HYPERTENSIONAHA.118.11212

8. Falkovskaya A.Yu., Mordovin V.F., Pekarskiy S.E., Ripp T.M., Zyubanova I.V., et al. Matrix metalloproteinases in patients with resistant hypertension and type 2 diabetes mellitus: relation with renal blood flow and kidney function. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2019;25(1):34-45. (In Russ.) https://doi.org/10.18705/1607-419X-2019-25-1-34-45

9. Nedogoda S.V., Barykina I.N., Salasyuk A.S., Sanina T.N., Smirnova V.O., Popova E.A. The effect of various classes of glucose-lowering medications on the blood vessel elasticity in patients with type 2 diabetes. Russian Journal of Cardiology. 2020;25(4):3766. (In Russ.) https://doi.org/10.15829/1560-4071-2020-3766

10. Koziolova N.A., Chernyavina A.I., Polyanskaya E.A. Selection of antyhyperglycemic agents in high-risk patients with type 2 diabetes mellitus (part 1). "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2016;22(4):330-348. (In Russ.) https://doi.org/10.18705/1607-419X-2016-22-4-330-348

11. Yozgatli K, Lefrandt JD, Noordzij MJ, Oomen PHN, Brouwer T, et al. Accumulation of advanced glycation end products is associated with macrovascular events and glycaemic control with microvascular complications in Type 2 diabetes mellitus. Diabet Med. 2018;35(9):1242-1248. https://doi.org/10.1111/dme.13651

12.